Page header

Recommendation of the President – Ultomiris (ravulizumab)

On 6 August 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 85/2024 on the evaluation of the drug Ultomiris (ravulizumab) within the framework of the drug program “Treatment of patients with generalized form of myasthenia gravis (G70.0)”

 

Publication in Public Information Bulletin (BIP) >>